Berlak, M., Tucker, E., Dorel, M., Winkler, A., McGearey, A., Rodriguez-Fos, E., Martins da Costa, B., Barker, K., Fyle, E.,
Calton, E., Eising, S., Ober, K., Hughes, D., Koutroumanidou, E., Carter, P., Stankunaite, R., Proszek, P., Jain, N., Rosswog,
C., Dorado-Garcia, H., Molenaar, J. J., Hubank, M., Barone, G., Anderson, J., Lang, P., Deubzer, H. E., Künkele, A., Fischer,
M., Eggert, A., Kloft, C., Henssen, A. G., Boettcher, M., Hertwig, F., Blüthgen, N., Chesler, L., & Schulte, J. H. (2022). Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment
lead to collateral vulnerabilities in neuroblastoma cells. Molecular Cancer, 21:.
doi:10.1186/s12943-022-01583-z.